SuperworthGilead Sciences GILD
- Market cap
- $193.5B
- PE
- n/m
- a loss over the last year
- Forward PE
- 17.2×
- 10y median 10.5×
- Price to sales
- 6.4×
- EV/EBIT
- 23.4×
- Revenue, 12 months
- $30.5B
- +6% on a year ago
- Net margin
- −10.6%
- Free cash flow yield
- 6.7%
Gilead Sciences trades at 6.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $30.5B over the last twelve months, up 6% on a year earlier with a −11% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.1B+0% | $7.1B−4% | $6.7B+5% | $7B+5% | $7.5B+7% | $7.6B+6% | $6.7B−0% | $7.1B+2% | $7.8B+3% | $7.9B+5% | $7B+4% | $7.8B+10% | |
| Cost of revenue | $1.6B+12% | $2.1B+50% | $1.6B+11% | $1.5B+7% | $1.6B+1% | $1.6B−24% | $1.5B−1% | $1.5B−3% | $1.6B−0% | $1.6B+3% | $1.4B−6% | $1.6B+5% |
| Gross profit | $5.5B−3% | $5B−16% | $5.1B+4% | $5.4B+5% | $6B+9% | $6B+19% | $5.1B−0% | $5.6B+3% | $6.2B+4% | $6.3B+5% | $5.5B+8% | $6.2B+12% |
| R&D | $1.5B+27% | $1.4B−9% | $1.5B+5% | $1.4B−4% | $1.4B−4% | $1.6B+17% | $1.4B−9% | $1.5B+10% | $1.3B−4% | $1.6B−4% | $1.4B−1% | $1.8B+18% |
| SG&A | $1.3B+8% | $1.6B−20% | $1.4B+4% | $1.4B−26% | $1.4B+9% | $1.9B+19% | $1.3B−9% | $1.4B−1% | $1.4B−5% | $1.8B−6% | $1.5B+15% | $1.9B+41% |
| $2.6B−8% | $1.6B−29% | −$4.3B | $2.6B+59% | $888M−66% | $2.5B+52% | $2.2B | $2.5B−6% | $3.3B+275% | $2B−19% | $2.6B+16% | −$10.4B | |
| Interest expense | $232M+1% | $252M+12% | $254M+10% | $237M+3% | $238M+3% | $249M−1% | $260M+2% | $254M+7% | $256M+8% | $255M+2% | $240M−8% | $247M−3% |
| Pre-tax income | $2.3B−5% | $1.7B−19% | −$4.5B | $2.1B+29% | $956M−59% | $2.2B+31% | $1.6B | $2.4B+18% | $3.6B+281% | $2.1B−4% | $2.6B+57% | −$10.3B |
| $146M−77% | $237M−41% | −$315M | $438M−20% | −$297M | $385M+62% | $334M | $468M+7% | $589M | −$105M | $559M+67% | $242M−48% | |
| Net income | $2.2B+22% | $1.4B−13% | −$4.2B | $1.6B+54% | $1.3B−43% | $1.8B+25% | $1.3B | $2B+21% | $3.1B+144% | $2.2B+22% | $2B+54% | −$10.5B |
| $1.73+22% | $1.14−12% | −$3.34 | $1.29+55% | $1.00−42% | $1.42+25% | $1.04 | $1.56+21% | $2.43+143% | $1.74+23% | $1.61+55% | −$8.45 | |
| 1.3B−0% | 1.3B−1% | 1.2B−1% | 1.3B−1% | 1.3B−0% | 1.3B+0% | 1.3B+1% | 1.3B+0% | 1.3B+0% | 1.3B−1% | 1.3B−0% | 1.2B−1% |
Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: 4 periods, Q4 FY08 to Q2 FY12: quarter's net income to common over its shares, to the cent. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 9 periods, Q4 FY08 to Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY12: share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x2). Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $7.8B | $7.8B to $7.9B | $2.18 | $1.95 to $2.32 | 14 |
| Q4 FY26 | $8.2B | $8.2B to $8.3B | $2.11 | $1.95 to $2.25 | 12 |
| Q1 FY27 | $7.5B | $7.4B to $7.8B | $2.29 | $2.25 to $2.42 | 5 |
| Q2 FY27 | $8.1B | $8B to $8.5B | $2.51 | $2.47 to $2.66 | 5 |
| Q3 FY27 | $8.2B | $8.1B to $8.6B | $2.55 | $2.51 to $2.70 | 5 |
| Q4 FY27 | $9.3B | $9.1B to $9.7B | $2.97 | $2.92 to $3.14 | 5 |
| Q1 FY28 | $8B | $7.9B to $8.3B | $0.00 | 6 | |
| Q2 FY28 | $8.4B | $8.3B to $8.8B | $0.00 | 6 |
Peers
Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GILDGilead Sciences | $193.5B | n/m | 18.8× | 17.2× | 6.4× | +6% | −10.6% |
| PFEPfizer | $171.2B | 39.5× | 15.8× | 10.9× | 2.7× | −0% | 6.8% |
| AMGNAmgen | $237.5B | 27.3× | 21.1× | 18.6× | 6.2× | +9% | 23.0% |
| BMYBristol-Myers Squibb | $125.6B | 13.5× | 19.9× | 10.4× | 2.6× | +3% | 18.9% |
| MRKMerck | $358.4B | 116× | 24.9× | 17.5× | 5.4× | +5% | 4.8% |
| ABBVAbbVie | $504.8B | 80.7× | 27.9× | 19.0× | 7.8× | +10% | 9.8% |
| JNJJohnson & Johnson | $635.8B | 40.0× | 24.3× | 23.4× | 6.4× | +8% | n/m |
| BIIBBiogen | $37B | 44.4× | 16.1× | 19.1× | 3.7× | +0% | 8.3% |
| LLYEli Lilly and | $1.2T | 42.7× | 41.4× | 33.9× | 15.0× | +50% | 33.5% |
| Peer median | $297.9B | 41.4× | 22.7× | 18.8× | 5.8× | +6% | 9.8% |
Investors who own it
Investors we follow who held Gilead Sciences at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Gilead Sciences
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .